ALTECH BATTERIES LTD — Capital/Financing Update 2018

Jan 2, 2018

==> picture [572 x 148] intentionally omitted <==

----- Start of picture text -----

ASX ANNOUNCEMENT
----- End of picture text -----

• 3 January 2018

Notice under Section 708A(5)(e) of the Corporations Act

On 3 January 2018 Altech Chemicals Limited ( Company ) completed the issue of A$3.0 million of shares to MAA Group Berhad and various associates of Melewar, resulting in total of 21,477,144 fully paid ordinary shares ( Shares ) being issued to various parties that fall within one of the exemptions set out in section 708 of the Corporations Act.

The Company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act.

The shares were issued without disclosure to investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act.

The Company, as at the date of this notice, has complied with:

• (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

• (b) Section 674 of the Corporations Act.

There is no excluded information for the purposes of Sections 708A(7) and (8) of the Corporations Act.

Yours faithfully

==> picture [86 x 51] intentionally omitted <==

Shane Volk Company Secretary

Altech Chemicals Limited

Rule
2.7,
3.10.3,
3.10.4,
3.10.5

**Appendix

3B**

**New

issue
announcement, application
for
quotation
of
additional
securities and
agreement**

Information
or
documents
not
available
now
must
be
given
to
ASX
as
soon
as
available.
Information
and documents
given
to
ASX
become
ASX’s
property
and
may
be
made
public.

Introduced
01/07/96
Origin:
Appendix
5
Amended
01/07/98,
01/09/99,
01/07/00,
30/09/01,
11/03/02,
01/01/03,
24/10/05,
01/08/12

3
January
2018

Name
of
entity

Altech
Chemicals
Limited

ABN 45
125
301
206

We
(the
entity)
give
ASX
the
following
information.

**Part

1
-­‐
All
issues**

				Part 1 - All issues	Part 1 - All issues
				You must complete the relevant sections (attach sheets if there is not enough space).
1				+Class of+securities issued or to be issued	ordinary shares
2				Number of+securities issued or to be
				issued (if known) or maximum	21,477,144 ordinary shares
				number which may be issued
3				Principal terms of the+securities (eg, if options, exercise price and expiry	fully paid ordinary shares at $0.14 per share
				date; if partly paid+securities, the amount outstanding and due dates for
				payment; if+convertible securities,
				the conversion price and dates for
				conversion)

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
2

4 Do the+securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 5 Issue price or consideration 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) 6a Is the entity an+eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h_in_ relation to the+securities the subject of this Appendix 3B, and comply with section 6i 6b The date the security holder resolution under rule 7.1A was passed 6c Number of+securities issued without security holder approval under rule 7.1	Yes
	$0.14 per share
	Continued development of the Company’s high purity alumina (HPA) project, working capital and general corporate purposes.
	No
	n/a
	nil

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
3

6d Number of+securities issued with security holder approval under rule 7.1A 6e Number of+securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting) 6f Number of securities issued under an exception in rule 7.2 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation. 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements 6i Calculate the entity’s remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements 7 Dates of entering +securities into uncertificated holdings or despatch of certificates 8 Number and+class of all+securities quoted on ASX (including the securities in section 2 if applicable)	Nil	Nil
	Nil
	7,142,857 to MAA Group Berhad (an entity controlled by Altech director Tunku Yaacob Khyra) and 14,334,287 to various parties associated with Melewar.
	n/a
	Nil
	7.1: 44,263,504 7.1A: -
	7,142,857 on 28 December 2017 14,334,287 on 3 January 2018
	Number	~~+~~Class
	426,540,532	Ordinary Shares

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
4

ASX ANNOUNCEMENT AND MEDIA 9 Number and+class of all+securities not quoted on ASX (_including_the securities in section 2 if applicable) 10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)
	Number	+Class
	RELEASE 5,200,000 10,000,000 5,500,000	Performance Rights: Employees & Consultants Performance Rights: Managing Director Performance Rights: Directors
	n/a

**Part

2
-­‐
Bonus
issue
or
pro
rata
issue**

11 Is security holder approval required? 12 Is the issue renounceable or non- renounceable? 13 Ratio in which the+securities will be offered 14 +Class of+securities to which the offer relates 15 +Record date to determine entitlements 16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements? 17 Policy for deciding entitlements in relation to fractions 18 Names of countries in which the entity has+security holders who will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

19 Closing date for receipt of acceptances or renunciations 20 Names of any underwriters 21 Amount of any underwriting fee or commission 22 Names of any brokers to the issue 23 Fee or commission payable to the broker to the issue 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of+security holders 25 If the issue is contingent on+security holders’ approval, the date of the meeting 26 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders 28 Date rights trading will begin (if applicable) 29 Date rights trading will end (if applicable) 30 How do+security holders sell their entitlements_in full_through a broker? 31 How do+security holders sell_part_of their entitlements through a broker and accept for the balance?

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
6

• 32 How
  do[+] security
  holders
  dispose
  of their
  entitlements
  (except
  by
  sale through
  a
  broker)?

• 33 +Despatch
  date

**Part

3
-­‐
Quotation
of
securities**

You
need
only
complete
this
section
if
you
are
applying
for
quotation
of
securities

• 34 Type
  of
  securities ( tick
  one )

• (a) ü[Securities
  described
  in
  Part
  1
  ]

• (b) All
  other
  securities

Example:
restricted
securities
at
the
end
of
the
escrowed
period,
partly
paid
securities
that
become
fully
paid, employee
incentive
share
securities
when
restriction
ends,
securities
issued
on
expiry
or
conversion
of
convertible securities

**Entities

that
have
ticked
box
34(a)**

**Additional

securities
forming
a
new
class
of
securities**

Tick
to
indicate
you
are
providing
the
information
or documents

• 35 If
  the[+] securities
  are[+] equity
  securities,
  the
  names
  of
  the
  20
  largest
  holders
  of
  the additional[+] securities,
  and
  the
  number
  and
  percentage
  of
  additional[+] securities held
  by
  those
  holders

• 36 If
  the[+] securities
  are[+] equity
  securities,
  a
  distribution
  schedule
  of
  the
  additional

• +securities
  setting
  out
  the
  number
  of
  holders
  in
  the
  categories 1
  -­‐
  1,000

• 1,001
  -­‐
  5,000

• 5,001
  -­‐
  10,000 10,001
  -­‐
  100,000

• 100,001
  and
  over

• 37 A
  copy
  of
  any
  trust
  deed
  for
  the
  additional[+] securities

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
7

**Entities

that
have
ticked
box
34(b)**

38 Number of securities for which +quotation is sought 39 Class of +securities for which quotation is sought 40 Do the+securities rank equally in all respects from the date of allotment with an existing+class of quoted+securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security) 42 Number and +class of all +securities quoted on ASX (_including_the securities in clause 38)
	Number	+Class

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
8

**Quotation

agreement**

• 1 +Quotation
  of
  our
  additional +securities
  is
  in
  ASX’s
  absolute
  discretion.
  ASX may
  quote
  the[+] securities
  on
  any
  conditions
  it
  decides.

• 2 We
  warrant
  the
  following
  to
  ASX.

• The
  issue
  of
  the[+] securities
  to
  be
  quoted
  complies
  with
  the
  law
  and
  is not
  for
  an
  illegal
  purpose.

• There
  is
  no
  reason
  why
  those[+] securities
  should
  not
  be
  granted + quotation.

• An
  offer
  of
  the[+] securities
  for
  sale
  within
  12
  months
  after
  their
  issue will
  not
  require
  disclosure
  under
  section
  707(3)
  or
  section
  1012C(6)
  of the
  Corporations
  Act.

Note:
An
entity
may
need
to
obtain
appropriate
warranties
from
subscribers
for
the
securities
in
order
to
be able
to
give
this
warranty

• Section
  724
  or
  section
  1016E
  of
  the
  Corporations
  Act
  does
  not
  apply
  to any
  applications
  received
  by
  us
  in
  relation
  to
  any[+] securities
  to
  be quoted
  and
  that
  no-­‐one
  has
  any
  right
  to
  return
  any[+] securities
  to
  be quoted
  under
  sections
  737,
  738
  or
  1016F
  of
  the
  Corporations
  Act
  at
  the time
  that
  we
  request
  that
  the[+] securities
  be
  quoted.

• If
  we
  are
  a
  trust,
  we
  warrant
  that
  no
  person
  has
  the
  right
  to
  return
  the +securities
  to
  be
  quoted
  under
  section
  1019B
  of
  the
  Corporations
  Act
  at the
  time
  that
  we
  request
  that
  the[+] securities
  be
  quoted.

• 3 We
  will
  indemnify
  ASX
  to
  the
  fullest
  extent
  permitted
  by
  law
  in
  respect
  of
  any claim,
  action
  or
  expense
  arising
  from
  or
  connected
  with
  any
  breach
  of
  the warranties
  in
  this
  agreement.

• 4 We
  give
  ASX
  the
  information
  and
  documents
  required
  by
  this
  form.

If
any information
or
document
not
available
now,
will
give
it
to
ASX
before +quotation
of
the +securities
begins.
We
acknowledge
that
ASX
is
relying
on the
information
and
documents.
We
warrant
that
they
are
(will
be)
true
and complete.

Sign
here: Date:
3
January
2018
( ~~Director/~~ Company
Secretary) Print
name: Shane
Volk

==
==
==
==
==

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
9

**Appendix

3B
–
Annexure
1**

**Calculation

of
placement
capacity
under
rule
7.1
and rule
7.1A
for[+] eligible
entities**

Introduced
01/08/12

**Part

1**

Rule 7.1 – Issues exceeding 15% of capital

Step 1: Calculate “A”, the base figure from which the placement capacity is calculated

==> picture [419 x 429] intentionally omitted <==

----- Start of picture text -----

Insert number of fully paid ordinary 266,188,312
securities on issue 12 months before date
of issue or agreement to issue
14,285,714 (Placement approved by
Add the following:
shareholders 29-5-17)
• Number of fully paid ordinary securities 15,090,939 (SPP 9-6-17)
issued in that 12 month period under an 1,759,092 (9-6-17 Placement approved by
exception in rule 7.2 shareholder)
1,162,979 (12-7-17 Placement approved by
• Number of fully paid ordinary securities shareholders)
issued in that 12 month period with
44,118,337 (1-11-17 Placement approved by
shareholder approval
shareholders)
• Number of partly paid ordinary 21,824,224 (1-11-17 Placement approved by
shareholders)
securities that became fully paid in that
12 month period 37,822,369 (11-12-17 Placement approved
by shareholders)
Note: 7,142,857 (28-12-17 Placement approved
• Include only ordinary securities here – by shareholders)
other classes of equity securities cannot
be added
• Include here (if applicable) the securities
the subject of the Appendix 3B to which
this form is annexed
• It may be useful to set out issues of
securities on different dates as separate
line items
Subtract the number of fully paid ordinary Nil
securities cancelled during that 12 month
period
“A” 409,394,823
----- End of picture text -----

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
10

Step 2: Calculate 15% of “A”

Step 2: Calculate 15% of “A”	Step 2: Calculate 15% of “A”
“B”	0.15 [Note: this value cannot be changed]
Multiply“A” by 0.15	61,409,223
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used
Insertnumber of equity securities issued or agreed to be issued in that 12 month period not counting_those issued: • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 _Note: • This applies to equity securities, unless specifically excluded – not just ordinary securities • Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed • It may be useful to set out issues of securities on different dates as separate line items	2,811,432 (Placement 1-12-17) 14,334,287 (Placement 3-1-18)
“C”	17,145,719
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1
“A” x 0.15 Note: number must be same as shown in Step 2	61,409,223
Subtract“C” Note: number must be same as shown in Step 3	17,145,719
Total[“A” x 0.15] – “C”	44,263,504 [Note: this is the remaining placement capacity under rule 7.1]

placement capacity under rule 7.1
“A” x 0.15	61,409,223
Note: number must be same as shown in
Step 2
Subtract“C”	17,145,719
Note: number must be same as shown in
Step 3
Total[“A” x 0.15] – “C”	44,263,504
	[Note: this is the remaining placement
	capacity under rule 7.1]

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
11

Part 2

Part 2	Part 2
Rule 7.1A – Additional placement capacity for eligible entities
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated
“A” Note: number must be same as shown in Step 1 of Part 1
Step 2: Calculate 10% of “A”
“D”	0.10 Note: this value cannot be changed
Multiply“A” by 0.10
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used
Insertnumber of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A Notes: • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items
“E”

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
12

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A
“A” x 0.10 Note: number must be same as shown in Step 2
Subtract“E” Note: number must be same as shown in Step 3
Total[“A” x 0.10] – “E”	Note: this is the remaining placement capacity under rule 7.1A

• See
  chapter
  19
  for
  defined
  terms.

01/08/2012

Appendix
3B
Page
13